Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges
Justine Maes, Bernard Pôlet, Janke Kleynhans, Filip Van Herpe, Karolien Goffin, Jeroen Dekervel, Philippe Nafteux, Baki Topal, Frederik Cleeren, Christophe M. Deroose · 2025
Read Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges by Justine Maes, Bernard Pôlet, Janke Kleynhans, Filip Van Herpe, Karolien Goffin, Jeroen Dekervel, Philippe Nafteux, Baki Topal, Frederik Cleeren, Christophe M. Deroose (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731750.txt.
Description
Justine Maes and co-authors review human studies of radioactive drugs that target a protein switched on in cancer support cells, in work from twenty twenty-five. The protein marks fibroblasts that help tumors grow. Drugs that home to it can both image and treat cancer.
Studies used isotopes such as lutetium, yttrium, and actinium tied to the targeting drug. Tumors took up the drug well, and safety looked favorable overall. Side effects were mostly mild, like fatigue, nausea, and low grade blood effects. Disease control rates were high in many reports. Tumor types varied and samples were small, which limits firm claims. The authors call for big prospective trials on dose and long term safety.
Catalog record
| CREATOR | Justine Maes, Bernard Pôlet, Janke Kleynhans, Filip Van Herpe, Karolien Goffin, Jeroen Dekervel, Philippe Nafteux, Baki Topal, Frederik Cleeren, Christophe M. Deroose |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |